Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

Background: There are no randomized trials comparing andexanet alfa and 4 factor prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I)-associated bleeds, and observational studies lack important patient characteristics. We pursued this study to demonstrate the fea...

Full description

Bibliographic Details
Main Authors:	Adam J. Singer, Mauricio Concha, James Williams, Caitlin S. Brown, Rafael Fernandes, Henry C. Thode Jr., Marylin Kirchman, Alejandro A. Rabinstein
Format:	Article
Language:	English
Published:	eScholarship Publishing, University of California 2023-08-01
Series:	Western Journal of Emergency Medicine
Online Access:	https://escholarship.org/uc/item/5hf50287

Similar Items

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
by: Elise Carpenter, et al.
Published: (2019-11-01)

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland
by: Anne Angelillo-Scherrer, et al.
Published: (2023-07-01)

Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events
by: Awatif Hafiz, et al.
Published: (2021-12-01)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
by: Victoria M. Stevens PharmD, BCCCP, et al.
Published: (2021-09-01)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
by: Kaatz S, et al.
Published: (2017-09-01)

Clinical pathways and outcomes of andexanet alfa administration for reversal of critical bleeding in patients on oral direct factor Xa inhibitors
by: Mark Goldin, et al.

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
by: Tessa Jaspers, et al.
Published: (2021-05-01)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
by: Sebastian Rauch, et al.
Published: (2022-06-01)

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey
by: Charles Fasanya MD, FRCS FACS, et al.
Published: (2024-03-01)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
by: Herm Jan M. Brinkman, et al.
Published: (2022-07-01)

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
by: Victoria M. Stevens PharmD, et al.
Published: (2019-12-01)

Successful use of an antithrombin for heparin resistance with andexanet alfa
by: Jun Honda, et al.
Published: (2023-05-01)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
by: Joseph Lewis BA, et al.
Published: (2022-05-01)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
by: C. James Watson, et al.
Published: (2019-11-01)

Andexanet alfa - what we know about this promising drug
by: Natalia Ilnicka, et al.
Published: (2023-09-01)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
by: Genmin Lu, et al.
Published: (2018-01-01)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
by: Alex C. Spyropoulos MD, et al.
Published: (2022-07-01)

How will UK hospitals use andexanet alfa? A review of local protocols
by: Paula Glancy, et al.
Published: (2023-02-01)

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
by: Alexander T. Cohen, et al.
Published: (2022-04-01)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-01-01)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-12-01)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
by: Hu TY, et al.
Published: (2016-02-01)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
by: Shaw Shaw, et al.
Published: (2023-07-01)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
by: Viktor Taune, et al.
Published: (2022-07-01)

Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study
by: John Vellek, et al.
Published: (2024-07-01)

Abstract 1122‐000165: Endovascular Intervention for a Thrombotic Adverse Event During Andexanet Alfa Infusion
by: Mohammad N Kayyali, et al.
Published: (2021-11-01)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
by: Siddharth Mehrotra, et al.
Published: (2022-12-01)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
by: Nina Haagenrud Schultz MD, PhD, et al.
Published: (2021-05-01)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
by: Jing Tao, et al.
Published: (2018-06-01)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
by: Olivia S. Costa, et al.
Published: (2022-06-01)

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
by: Shohei Hamada, et al.
Published: (2024-02-01)

A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19
by: Sandra Jonmarker, et al.
Published: (2023-10-01)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
by: Eva N. Hamulyák, et al.
Published: (2021-01-01)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
by: Megan A. Rech, et al.
Published: (2020-12-01)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
by: Daniël Verhoef, et al.
Published: (2017-09-01)

Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro<sup>®</sup> Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients
by: Daniel Oberladstätter, et al.
Published: (2021-08-01)

Case report: First treatment of acute ischaemic stroke in a patient on active rivaroxaban therapy using andexanet alfa and rtPA combined with early complete recovery
by: Bartosz Karaszewski, et al.
Published: (2023-10-01)

Efficacy and Toxicity of Factor Xa Inhibitors
by: Maryna Bondarenko, et al.
Published: (2013-02-01)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
by: Milan Remko, et al.
Published: (2016-02-01)

Direct factor Xa inhibitor in the prevention of thromboembolism
by: Viktor Meretskyi, et al.
Published: (2019-01-01)